Absorica LD

6 ADVERSE REACTIONS The following adverse reactions with ABSORICA/ABSORICA LD or other isotretinoin capsule products are described in more detail in other sections of the labeling: • Embryo-Fetal Toxicity [see Warnings and Precautions ( 5.1 )] • Psychiatric Disorders [see Warnings and Precautions ( 5.4 )] • Intracranial Hypertension (Pseudotumor Cerebri) [see Warnings and Precautions ( 5.5 )] • Serious Skin Reactions [see Warnings and Precautions ( 5.6 )] • Pancreatitis [see Warnings and Precautions ( 5.7 )] • Lipid Abnormalities [see Warnings and Precautions ( 5.8 )] • Hearing Impairment [see Warnings and Precautions ( 5.9 )] • Hepatotoxicity [see Warnings and Precautions ( 5.10 )] • Inflammatory Bowel Disease [see Warnings and Precautions ( 5.11 )] • Musculoskeletal Abnormalities [see Warnings and Precautions ( 5.12 )] • Ocular Abnormalities [see Warnings and Precautions ( 5.13 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.14 )] The following adverse reactions associated with the use of isotretinoin capsules were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dose Relationship Cheilitis and hypertriglyceridemia were dose related. Body as a Whole Fatigue, irritability, pain, allergic reactions, systemic hypersensitivity, edema, lymphadenopathy, weight loss. Cardiovascular Vascular thrombotic disease, stroke, palpitation, tachycardia. Endocrine/Metabolism and Nutritional Decreased appetite, weight fluctuation, alterations in blood sugar. Gastrointestinal Dry lips, chapped lips, cheilitis, nausea, constipation, diarrhea, abdominal pain, vomiting, inflammatory bowel disease, hepatitis, pancreatitis, bleeding and inflammation of the gums, colitis, esophagitis, esophageal ulceration, ileitis. Hematologic Anemia and decreased RBC parameters, thrombocytopenia, increased platelet counts, decreased WBC counts, severe neutropenia, rare reports of agranulocytosis. Infections and Infestations Nasopharyngitis, hordeolum, infections (including disseminated herpes simplex and upper respiratory tract infection). Laboratory Abnormalities The following lab tests were increased: creatine phosphokinase (CPK), triglycerides, alanine aminotransferase (SGPT), aspartate aminotransferase (SGOT), gamma-glutamyltransferase (GGTP), cholesterol, low density lipoprotein (LDL), alkaline phosphatase, bilirubin, LDH, fasting blood glucose, uric acid, and sedimentation rate. However, high density lipoprotein (HDL) was decreased. Urine findings included increased white cells, proteinuria, microscopic or gross hematuria. Musculoskeletal and Connective Tissue Decreases in bone mineral density, musculoskeletal symptoms (sometimes severe) including back pain, arthralgia, musculoskeletal pain, neck pain, extremity pain, myalgia, musculoskeletal stiffness [see Warnings and Precautions (5.12)] , skeletal hyperostosis, calcification of tendons and ligaments, premature epiphyseal closure, tendonitis, arthritis, transient chest pain, and rare reports of rhabdomyolysis. Neurological Headache, syncope, intracranial hypertension (pseudotumor cerebri), dizziness, drowsiness, lethargy, malaise, nervousness, paresthesia, seizures, stroke, weakness. Psychiatric Suicidal ideation, insomnia, anxiety, depression, irritability, panic attack, anger, euphoria, violent behaviors, emotional instability, suicide attempts, suicide, aggression, psychosis and auditory hallucinations. Of the patients reporting depression, some reported that the depression subsided with discontinuation of therapy and recurred with reinstitution of therapy. Reproductive System Abnormal menses, sexual dysfunction, including erectile dysfunction, decreased libido, decreased vaginal lubrication, and vaginal dryness. Respiratory Epistaxis, nasal dryness, bronchospasm (with or without a history of asthma), respiratory infection, voice alteration. Skin and Subcutaneous Tissue Dry skin, dermatitis, eczema, rash, contact dermatitis, alopecia, pruritus, sunburn, erythema, acne fulminans, alopecia(which in some cases persisted), bruising, dry nose, eruptive xanthomas, erythema multiforme, flushing, skin fragility, hair abnormalities, hirsutism, hyperpigmentation and hypopigmentation, nail dystrophy, paronychia, peeling of palms and soles, photoallergic/photosensitizing reactions, pruritus, pyogenic granuloma, rash (including facial erythema, seborrhea, and eczema), Stevens-Johnson syndrome, increased sunburn susceptibility, sweating, toxic epidermal necrolysis, urticaria,vasculitis (including granulomatosis with polyangiitis), abnormal wound healing (delayed healing or exuberant granulation tissue with crusting). Senses Hearing: tinnitus and hearing impairment. Ocular : dry eyes, reduced visual acuity, blurred vision, eye pruritis, eye irritation, asthenopia, decreased night vision, ocular hyperemia, increased lacrimation, conjunctivitis, corneal opacities, decreased night vision which may persist, cataracts, color vision disorder, conjunctivitis, eyelid inflammation, keratitis, optic neuritis, photobia, visual disturbances. Renal and Urinary Glomerulonephritis. Most common adverse reactions (incidence ≥5%) are: dry lips, dry skin, back pain, dry eye, arthralgia, epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, increased creatine kinase, cheilitis, musculoskeletal discomfort, upper respiratory tract infection, reduced visual acuity. (6) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or iPLEDGE at (1-866-495-0654).

4 CONTRAINDICATIONS • Pregnancy ( 4.1 , 8.1 ) • Hypersensitivity to this product or any of its components ( 4.2 , 5.14 ) 4.1 Pregnancy ABSORICA/ABSORICA LD is contraindicated in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. 4.2 Hypersensitivity ABSORICA/ABSORICA LD is contraindicated in patients with hypersensitivity to isotretinoin (or Vitamin A, given the chemical similarity to isotretinoin) or to any of its components (anaphylaxis and other allergic reactions have occurred) [see Warnings and Precautions (5.14) ] .

11 DESCRIPTION ABSORICA ABSORICA (isotretinoin) Capsules contain 10 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg of isotretinoin (a retinoid) in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, each capsule contains the following inactive ingredients: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems: •10 mg – iron oxide (yellow) and titanium dioxide; •20 mg – iron oxide (red), and titanium dioxide; •25 mg – FD&C Blue #1, FD&C Yellow #5 [see Warnings and Precautions (5.14) ] , FD&C Yellow #6 and titanium dioxide; •30 mg – iron oxide (black, red and yellow) and titanium dioxide; •35 mg – FD&C Blue #2, iron oxide (black, red and yellow) and titanium dioxide; •40 mg – iron oxide (black, red and yellow) and titanium dioxide. ABSORICA LD ABSORICA LD (isotretinoin) Capsules contain 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg of micronized isotretinoin (a retinoid) in suspension filled in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, USP each capsule contains the following inactive ingredients: butylated hydroxy anisole, gelatin, hard gelatin capsule shell, polysorbate 80 and soybean oil. The gelatin capsules contain the following dye systems: •8 mg – D&C Yellow #10, FD&C Blue #1, FD&C Red #40 and titanium dioxide •16 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •20 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •24 mg – D&C Yellow #10, FD&C Yellow #6 and titanium dioxide •28 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •32 mg – ferrosoferric oxide, ferric oxide (red and yellow) and titanium dioxide The imprinting ink of 8 mg, 16 mg, 24 mg and 32 mg capsules contain the following ingredients: potassium hydroxide, propylene glycol, shellac and titanium dioxide. The imprinting ink of 20 mg and 28 mg capsules contain the following ingredients: ferrosoferric oxide, propylene glycol and shellac glaze. Isotretinoin Chemically, isotretinoin is 13- cis -retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow to orange crystalline powder with a molecular weight of 300.44. It is practically insoluble in water, soluble in chloroform and sparingly soluble in alcohol and in isopropyl alcohol. The structural formula is: ABSORICA meets USP Dissolution Test 3. For ABSORICA LD, FDA approved dissolution test differs from the USP. spl-absorica-str.jpg

2 DOSAGE AND ADMINISTRATION • ABSORICA is not substitutable with ABSORICA LD because of different bioavailability and recommended dosage. ( 2.1 , 5.3 ) • Recommended dosage for: o ABSORICA is 0.5 to 1 mg/kg/day given in two divided doses without regard to meals for 15 to 20 weeks ( 2.1 ) o ABSORICA LD is 0.4 to 0.8 mg/kg/day given in two divided doses without regard to meals for 15 to 20 weeks ( 2.1 ) • Adult patients with very severe disease (scarring, trunk involvement) may increase dosage to 2 mg/kg/day of ABSORICA (1.6 mg/kg/day of ABSORICA LD) in divided doses. ( 2.1 ) • Once daily dosing is not recommended. ( 2.1 ) • If a dose of ABSORICA/ABSORICA LD is missed, just skip that dose. Do not take two doses of ABSORICA/ABSORICA LD at the same time. ( 2.1 ) • Perform pregnancy tests prior to prescribing, each month during therapy, end of therapy, and one month after discontinuation. ( 2.3 , 8.3 ) • Prior to prescribing, perform fasting lipid profile and liver function tests. ( 2.3 ) 2.1 Recommended Dosage ABSORICA is not substitutable with ABSORICA LD [see Warnings and Precautions (5.3) ] . The recommended dosage of: • ABSORICA is 0.5 to 1 mg/kg/day given in two divided doses with or without meals for 15 to 20 weeks (see Table 1). • ABSORICA LD is 0.4 to 0.8 mg/kg/day given in two divided doses with or without meals for 15 to 20 weeks (see Table 2). To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid. During treatment, the dosage may be adjusted according to response of the disease and/or adverse reactions, some of which may be dose-related. Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dosage adjustments up to 2 mg/kg/day for ABSORICA (1.6 mg/kg/day for ABSORICA LD) in divided doses, as tolerated. The safety and effectiveness of once daily dosing with ABSORICA/ABSORICA LD has not been established and is not recommended. If a dose of ABSORICA/ABSORICA LD is missed, just skip that dose. Do not take two doses of ABSORICA/ ABSORICA LD at the same time. Table 1: ABSORICA Daily Dosage by Body Weight 1 Body Weight Total Daily Dosage (mg) 1 0.5 mg/kg 1 mg/kg 2 mg/kg 40 kg 20 40 80 50 kg 25 50 100 60 kg 30 60 120 70 kg 35 70 140 80 kg 40 80 160 90 kg 45 90 180 100 kg 50 100 200 1 Administer in two divided doses with or without meals Table 2: ABSORICA LD Daily Dosage by Body Weight 1 Body Weight Total Daily Dosage (mg) 1 0.4 mg/kg 0.8 mg/kg 1.6 mg/kg 40 kg 16 32 64 50 kg 20 40 80 60 kg 24 48 96 70 kg 28 56 112 80 kg 32 64 128 90 kg 36 72 144 100 kg 40 80 160 1 Administer in two divided doses with or without meals 2.2 Duration of Use A normal course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, may discontinue ABSORICA/ABSORICA LD. After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, may initiate a second course of ABSORICA/ABSORICA LD in patients who have completed skeletal growth. The use of another course of ABSORICA/ABSORICA LD therapy is not recommended before a two-month waiting period because the patient’s acne may continue to improve after a 15 to 20-week course of therapy. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of ABSORICA/ABSORICA LD, even in low dosages, has not been studied, and is not recommended. The effect of long-term use of ABSORICA/ABSORICA LD on bone loss is unknown [see Warnings and Precautions (5.12) ] . 2.3 Laboratory Testing Prior to Administration The following laboratory testing must be completed prior to ABSORICA/ABSORICA LD use: • Pregnancy testing: Ensure patient is not pregnant prior to administering ABSORICA/ABSORICA LD [see Contraindications (4) and Use in Specific Populations (8.1 , 8.3) ] • A fasting lipid profile including triglycerides [see Warnings and Precautions (5.8 , 5.15) ] . • Liver function tests [see Warnings and Precautions (5.10 , 5.15) ] .

1 INDICATIONS AND USAGE ABSORICA and ABSORICA LD are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use : If a second course of ABSORICA/ABSORICA LD therapy is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy [see Dosage and Administration (2.2) ]. ABSORICA and ABSORICA LD are retinoids indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. (1) Limitations of Use: If a second course of ABSORICA/ABSORICA LD therapy is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy. (1)

10 OVERDOSAGE In humans, isotretinoin overdosage has been associated with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia. These symptoms quickly resolved without apparent residual effects. Patients who can become pregnant who present with an ABSORICA/ABSORICA LD overdosage should be evaluated for pregnancy. Because an overdosage would be expected to result in higher levels of isotretinoin in semen than found during a normal treatment course, male patients treated with ABSORICA/ABSORICA LD should use a condom, or avoid reproductive sexual activity with a patient who is or might become pregnant, for 1 month after the overdose. All patients with ABSORICA/ABSORICA LD overdose should not donate blood for at least 1 month.

7 DRUG INTERACTIONS • Vitamin A: may cause additive adverse reactions (7.1) • Tetracyclines: avoid concomitant use (7.2) 7.1 Vitamin A ABSORICA/ABSORICA LD is closely related to vitamin A. Therefore, the use of both vitamin A and ABSORICA/ABSORICA LD at the same time may lead to vitamin A related adverse reactions. Patients treated with ABSORICA/ABSORICA LD should be advised against taking supplements containing Vitamin A to avoid additive toxic effects. 7.2 Tetracyclines Concomitant treatment with ABSORICA/ABSORICA LD and tetracyclines should be avoided because isotretinoin use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines [see Warnings and Precautions (5.5) ] . 7.3 Phenytoin Phenytoin is known to cause osteomalacia. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss between phenytoin and isotretinoin. Therefore, caution should be exercised when using these drugs together. 7.4 Systemic Corticosteroids Systemic corticosteroids are known to cause osteoporosis. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss with concomitant use of systemic corticosteroids and isotretinoin. Therefore, caution should be exercised when using these drugs together. 7.5 Norethindrone/ethinyl estradiol In a trial of 31 premenopausal female patients with severe recalcitrant nodular acne receiving norethindrone and ethinyl estradiol as an oral contraceptive agent, isotretinoin capsules within the recommended dosage, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Although this study did not show any clinically significant interaction between isotretinoin and norethindrone, it is not known if there is an interaction between isotretinoin with other progestins.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action ABSORICA/ABSORICA LD is a retinoid, which when administered at the recommended dosage [see Dosage and Administration (2.1) ] , inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with isotretinoin capsules and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation. The exact mechanism of action of ABSORICA/ABSORICA LD in the treatment of severe recalcitrant nodular acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of ABSORICA/ABSORICA LD are unknown. 12.3 Pharmacokinetics No clinically significant differences in the pharmacokinetics of isotretinoin between patients with nodular acne and healthy subjects without acne were reported in published literature. Absorption Following ABSORICA Administration The ABSORICA mean T max was 6.4 hours under fed conditions and 2.9 hours under fasting conditions following administration of a single 40 mg dose. Effect on Food No clinically significant differences in ABSORICA pharmacokinetics were observed following administration with a modified high-fat, high-calorie meal (123.2 calories from protein, 265.6 calories from carbohydrates, and 468 calories from fat; total calories 857 calories) with reduced vitamin A content. The mean AUC 0-t and C max of isotretinoin were 6095 ng*hr/mL and 369 ng/mL, respectively, following administration of a single 40 mg ABSORICA dose under fed conditions; which were approximately 50% and 26% higher, respectively, compared to fasting conditions. However, ABSORICA may be given with or without meals [see Dosage and Administration (2.1) ]. Absorption Following ABSORICA LD Administration The ABSORICA LD median T max was 5 hours under fed conditions and 3.5 hours under fasting conditions following administration of a single 32 mg dose. Effect on Food No clinically significant differences in ABSORICA LD pharmacokinetics were observed following administration with a high-fat, high-calorie meal (150 calories from protein, 250 calories from carbohydrates, and 500 calories from fat; total calories 900 calories). The mean AUC 0-t and C max of isotretinoin were 10209 ng*hr/mL and 646 ng/mL, respectively, following administration of a single 32 mg ABSORICA LD dose under fed conditions; which were approximately 20% and 6% higher, respectively, compared to fasting conditions. However, ABSORICA LD may be given with or without meals [see Dosage and Administration (2.1) ] . Distribution Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin. Elimination The mean elimination half-lives of isotretinoin and its 4-oxo-isotretinoin metabolite were: •18 hours and 38 hours, respectively, after a single oral ABSORICA 40 mg dose. •Approximately 24 hours and 38 hours, respectively, after a single oral ABSORICA LD 32 mg dose. Metabolism : Isotretinoin is primarily metabolized by CYP2C8, 2C9, 3A4, and 2B6 in vitro. Isotretinoin and its metabolites are further metabolized into conjugates. Following oral administration of isotretinoin capsules, at least three metabolites (4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxo-retinoic acid (4-oxo-tretinoin)) have been identified in human plasma. The extent of formation of all metabolites was higher under fed conditions. All of these metabolites possess retinoid activity in vitro. The clinical significance is unknown. Excretion : Following oral administration of an 80 mg dose of radiolabeled-isotretinoin as a liquid suspension, the metabolites of isotretinoin were excreted in feces and urine in relatively equal amounts (total of 65% to 83%). Specific Populations Pediatric Patients: No clinically significant differences in the pharmacokinetics of isotretinoin were observed based on age (12 to 15 years (n=38), and ≥18 years (n=19)). In both age groups, 4-oxo-isotretinoin was the major metabolite; tretinoin and 4-oxo-tretinoin were also observed [see Use in Specific Populations (8.4) ] . Drug Interaction Studies No clinically significant differences in the pharmacokinetics of phenytoin (CYP2C9 substrate) were observed when used concomitantly with isotretinoin.

12.1 Mechanism of Action ABSORICA/ABSORICA LD is a retinoid, which when administered at the recommended dosage [see Dosage and Administration (2.1) ] , inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with isotretinoin capsules and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation. The exact mechanism of action of ABSORICA/ABSORICA LD in the treatment of severe recalcitrant nodular acne is unknown.

12.2 Pharmacodynamics The pharmacodynamics of ABSORICA/ABSORICA LD are unknown.

12.3 Pharmacokinetics No clinically significant differences in the pharmacokinetics of isotretinoin between patients with nodular acne and healthy subjects without acne were reported in published literature. Absorption Following ABSORICA Administration The ABSORICA mean T max was 6.4 hours under fed conditions and 2.9 hours under fasting conditions following administration of a single 40 mg dose. Effect on Food No clinically significant differences in ABSORICA pharmacokinetics were observed following administration with a modified high-fat, high-calorie meal (123.2 calories from protein, 265.6 calories from carbohydrates, and 468 calories from fat; total calories 857 calories) with reduced vitamin A content. The mean AUC 0-t and C max of isotretinoin were 6095 ng*hr/mL and 369 ng/mL, respectively, following administration of a single 40 mg ABSORICA dose under fed conditions; which were approximately 50% and 26% higher, respectively, compared to fasting conditions. However, ABSORICA may be given with or without meals [see Dosage and Administration (2.1) ]. Absorption Following ABSORICA LD Administration The ABSORICA LD median T max was 5 hours under fed conditions and 3.5 hours under fasting conditions following administration of a single 32 mg dose. Effect on Food No clinically significant differences in ABSORICA LD pharmacokinetics were observed following administration with a high-fat, high-calorie meal (150 calories from protein, 250 calories from carbohydrates, and 500 calories from fat; total calories 900 calories). The mean AUC 0-t and C max of isotretinoin were 10209 ng*hr/mL and 646 ng/mL, respectively, following administration of a single 32 mg ABSORICA LD dose under fed conditions; which were approximately 20% and 6% higher, respectively, compared to fasting conditions. However, ABSORICA LD may be given with or without meals [see Dosage and Administration (2.1) ] . Distribution Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin. Elimination The mean elimination half-lives of isotretinoin and its 4-oxo-isotretinoin metabolite were: •18 hours and 38 hours, respectively, after a single oral ABSORICA 40 mg dose. •Approximately 24 hours and 38 hours, respectively, after a single oral ABSORICA LD 32 mg dose. Metabolism : Isotretinoin is primarily metabolized by CYP2C8, 2C9, 3A4, and 2B6 in vitro. Isotretinoin and its metabolites are further metabolized into conjugates. Following oral administration of isotretinoin capsules, at least three metabolites (4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxo-retinoic acid (4-oxo-tretinoin)) have been identified in human plasma. The extent of formation of all metabolites was higher under fed conditions. All of these metabolites possess retinoid activity in vitro. The clinical significance is unknown. Excretion : Following oral administration of an 80 mg dose of radiolabeled-isotretinoin as a liquid suspension, the metabolites of isotretinoin were excreted in feces and urine in relatively equal amounts (total of 65% to 83%). Specific Populations Pediatric Patients: No clinically significant differences in the pharmacokinetics of isotretinoin were observed based on age (12 to 15 years (n=38), and ≥18 years (n=19)). In both age groups, 4-oxo-isotretinoin was the major metabolite; tretinoin and 4-oxo-tretinoin were also observed [see Use in Specific Populations (8.4) ] . Drug Interaction Studies No clinically significant differences in the pharmacokinetics of phenytoin (CYP2C9 substrate) were observed when used concomitantly with isotretinoin.

20230612

18

3 DOSAGE FORMS AND STRENGTHS ABSORICA and ABSORICA LD have different dosage regimens [see Dosage and Administration (2.1) ] . Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable. ABSORICA is available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg capsules. • 10 mg: Dark yellow, opaque, capsule imprinted with black ink “ G 240 ” on cap and “ 10 ” on the body • 20 mg: Red, opaque, capsule imprinted with black ink “ G 241 ” on cap and “ 20 ” on the body • 25 mg: Green, opaque, capsule imprinted with white ink “ G 342 ” on cap and “ 25 ” on the body • 30 mg: Brown, opaque, capsule imprinted with white ink “ G 242 ” on cap and “ 30 ” on the body • 35 mg: Dark blue, opaque, capsule imprinted with white ink “ G 343 ” on cap and “ 35 ” on the body • 40 mg: Brown and red, capsule imprinted with white ink “ G 325 ” on cap and “ 40 ” on the body ABSORICA LD is available in 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg opaque-printed, hard-gelatin capsules. • 8 mg: A size 3, light green with a colorless band (the cap is printed in white with “RL29” and the body is printed in white with “ RL29 ”). • 16 mg : A size 2, dark blue with a colorless band (the cap is printed in white with “RL30” and the body is printed in white with “ RL30 ”). • 20 mg : A size 1, dark pink with a colorless band (the cap is printed in black with “RL33”and the body is printed in black with “ RL33 ”). • 24 mg : A size 1, yellow with a colorless band (the cap is printed in white with “RL31” and the body is printed in white with “ RL31 ”). • 28 mg : A size 0, light blue, with a colorless band (the cap is printed in black with “RL34” and the body is printed in black with “ RL34 ”). • 32 mg : A size 0, caramel with a colorless band (the cap is printed in white with “RL32” and the body is printed in white with “ RL32 ”). ABSORICA Capsules: 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg (3) ABSORICA LD Capsules: 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg (3)

Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G240;10 Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE FERRIC OXIDE RED POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G241;20 Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC SODIUM HYDROXIDE PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G242;30 Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC SODIUM HYDROXIDE PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G325;40 Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE PROPYLENE GLYCOL SHELLAC SODIUM HYDROXIDE FD&C BLUE NO. 1 FD&C YELLOW NO. 5 FD&C YELLOW NO. 6 PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G342;25 Absorica isotretinoin ISOTRETINOIN ISOTRETINOIN SOYBEAN OIL SORBITAN MONOOLEATE PROPYL GALLATE TITANIUM DIOXIDE PROPYLENE GLYCOL SHELLAC SODIUM HYDROXIDE FD&C BLUE NO. 2 FERROSOFERRIC OXIDE FERRIC OXIDE RED FERRIC OXIDE YELLOW PEG-32 HYDROGENATED PALM GLYCERIDES GELATIN, UNSPECIFIED G343;35 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C RED NO. 40 POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE light green opaque-printed, hard-gelatin RL29 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL FD&C BLUE NO. 1 FD&C RED NO. 40 POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE dark blue opaque-printed, hard-gelatin RL30 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL FD&C BLUE NO. 1 FD&C RED NO. 40 FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE dark pink opaque-printed, hard-gelatin RL33 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL D&C YELLOW NO. 10 FD&C YELLOW NO. 6 POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE opaque-printed, hard-gelatin RL31 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL FD&C BLUE NO. 1 FD&C RED NO. 40 FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE light blue opaque-printed, hard-gelatin RL34 Absorica LD isotretinoin ISOTRETINOIN ISOTRETINOIN BUTYLATED HYDROXYANISOLE GELATIN, UNSPECIFIED POLYSORBATE 80 SOYBEAN OIL FERROSOFERRIC OXIDE FERRIC OXIDE RED FERRIC OXIDE YELLOW POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC TITANIUM DIOXIDE Caramel opaque-printed, hard-gelatin RL32

13.2 Animal Toxicology In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, fibrosis and inflammation of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area).

13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area) for greater than 18 months, there was a dose-related increased incidence of pheochromocytoma relative to controls. The incidence of adrenal medullary hyperplasia was also increased at the higher dosage in both sexes. The relatively high level of spontaneous pheochromocytomas occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to humans is uncertain. The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative, while in the second laboratory, a weakly positive response (less than 1.6 times background) was noted in S. typhimurium TA100 when the assay was conducted with metabolic activation. No dose response effect was seen, and all other strains were negative. Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, S. cerevisiae D7 assay, in vitro clastogenesis assay with human-derived lymphocytes, and unscheduled DNA synthesis assay) were all negative. In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area). In dogs, testicular atrophy was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area). In general, there was microscopic evidence for appreciable depression of spermatogenesis, but some sperm were observed in all testes examined, and in no instance were completely atrophic tubules seen.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area) for greater than 18 months, there was a dose-related increased incidence of pheochromocytoma relative to controls. The incidence of adrenal medullary hyperplasia was also increased at the higher dosage in both sexes. The relatively high level of spontaneous pheochromocytomas occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to humans is uncertain. The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative, while in the second laboratory, a weakly positive response (less than 1.6 times background) was noted in S. typhimurium TA100 when the assay was conducted with metabolic activation. No dose response effect was seen, and all other strains were negative. Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, S. cerevisiae D7 assay, in vitro clastogenesis assay with human-derived lymphocytes, and unscheduled DNA synthesis assay) were all negative. In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area). In dogs, testicular atrophy was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area). In general, there was microscopic evidence for appreciable depression of spermatogenesis, but some sperm were observed in all testes examined, and in no instance were completely atrophic tubules seen. 13.2 Animal Toxicology In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 or 5.3 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, fibrosis and inflammation of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical ABSORICA dosage of 1 mg/kg/day or the recommended clinical ABSORICA LD dosage of 0.8 mg/kg/day, respectively, after normalization for total body surface area).

NDA211913

Absorica LD

isotretinoin

10631-002

HUMAN PRESCRIPTION DRUG

ORAL

Absorica 10 mg Blister spl-absorica-wallet-10mg

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Embryo-Fetal Toxicity There is an extremely high risk of life-threatening birth defects when ABSORICA/ABSORICA LD is used in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Instruct patients who can become pregnant that they must not be pregnant during or up to one month after ABSORICA/ABSORICA LD therapy. Instruct patients to not donate blood during ABSORICA/ABSORICA LD therapy and for 1 month following discontinuation to avoid blood donation to a pregnant patient. iPLEDGE ABSORICA and ABSORICA LD are available only through a restricted program called iPLEDGE [see Warnings and Precautions (5.2) ] . Inform patients who can become pregnant of the following notable requirements. These patients must: • Sign an informed consent form to be enrolled in the program • Comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.3) ] • Demonstrate comprehension of the safe-use conditions of the program every month • Obtain the prescription within 7 days of the pregnancy test collection Inform patients who cannot become pregnant of the following notable requirements. These patients must sign an informed consent form to enroll in the program and they must obtain the prescription within 30 days of the office visit. ABSORICA/ABSORICA LD is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain ABSORICA/ABSORICA LD [see Warnings and Precautions (5.2) ]. Lactation Because of the potential for serious adverse reactions in nursing infants from isotretinoin, advise patients that breastfeeding is not recommended during treatment with ABSORICA/ABSORICA LD, and for at least 8 days after the last dose of ABSORICA/ABSORICA LD [see Use in Specific Populations (8.2) ] . Psychiatric Disorders Instruct patients and/or their caregivers/families that ABSORICA/ABSORICA LD may cause depression, psychosis, suicidal ideation, suicide attempts, and aggressive or violent behavior. Instruct patients to read the Recognizing Psychiatric Disorders in Adolescents and Young Adults brochure prior to taking ABSORICA/ABSORICA LD. Instruct patients to stop ABSORICA/ABSORICA LD and to contact a healthcare provider if they develop any of these signs or symptoms [see Warnings and Precautions (5.4) ] . Important Administration Instructions To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid [see Dosage and Administration (2.1) ] . Intracranial Hypertension (Pseudotumor Cerebri) Advise patients that intracranial hypertension (pseudotumor cerebri) has occurred with ABSORICA/ABSORICA LD use including concomitant use with tetracyclines. Thus, advise patients to avoid concomitant use with tetracyclines and to discontinue ABSORICA/ABSORICA LD immediately if they have symptoms of intracranial hypertension [see Warningsand Precautions (5.5) ] . Serious Skin Reactions Advise patients that severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported in patients treated with isotretinoin and to discontinue ABSORICA/ABSORICA LD if clinically significant skin reactions occur [see Warnings and Precautions (5.6) ] . Inflammatory Bowel Disease Advise patients that inflammatory bowel disease (including regional ileitis) have occurred with isotretinoin use including those without a prior history of IBD and if they experience IBD symptoms, they should discontinue ABSORICA/ABSORICA LD immediately [see Warnings and Precautions (5.11) ] . Musculoskeletal Abnormalities Inform patients that: • There have been reports of osteoporosis and fractures and that isotretinoin may have a negative effect on bone mineral density [see Warnings and Precautions (5.12) ] . • Isotretinoin use has been associated with musculoskeletal abnormalities (e.g., arthralgia, back pain) [see Warnings and Precautions (5.12) ] . Inform adolescents and their families that isotretinoin use in adolescents who participated in sports with repetitive impact increase their risk of spondylolisthesis or hip growth plate injuries [see Warnings and Precautions (5.12) ] . Inform pediatric patients and their caregivers that pediatric patients treated with isotretinoin capsules developed back pain including severe back pain, and arthralgias including severe arthralgias [see Use in Specific Populations (8.4) ] . Ocular Abnormalities Inform patients that they may experience dry eyes, corneal opacities, and decreased night vision and contact lens wearers may experience decreased tolerance to contact lenses during and after therapy [see Warnings and Precautions (5.13) ] . Rhabdomyolysis Inform patients there have been rare postmarketing reports of rhabdomyolysis in patients treated with isotretinoin capsules, some associated with strenuous physical activity [see Warnings and Precautions (5.15) ] . Hypersensitivity Reactions Given that anaphylactic reactions and other allergic reactions have been reported in patients treated with isotretinoin capsules, instruct the patient to discontinue ABSORICA/ABSORICA LD and contact their healthcare provider if they have a severe allergic reaction [see Warnings and Precautions (5.14) ] . Lipid Abnormalities Instruct patients that hypertriglyceridemia, decreased HDL, and increased cholesterol levels were reported in patients treated with isotretinoin capsules [see Warnings and Precautions (5.8) ] . Additional Instructions Inform patients: • To not share ABSORICA/ABSORICA LD with anyone else because of the risk of birth defects and other serious adverse reactions. • That transient exacerbation (flare) of acne has been seen, generally during the initial period of therapy. • That wax epilation and skin resurfacing procedures (such as dermabrasion, laser) should be avoided during ABSORICA/ABSORICA LD therapy and for at least 6 months thereafter due to the possibility of scarring. • To avoid prolonged exposure to UV rays or sunlight. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 ABSORICA and ABSORICA LD are registered trademarks of Sun Pharmaceutical Industries, Inc. All other trademarks are property of their respective owners. ABSORICA LD 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg is protected by US Patent No. US 9,700,535 and US 9,750,711.

Medication Guide MEDICATION GUIDE ABSORICA (ab-sore-i-kah) (isotretinoin) capsules ABSORICA (ab-sore-i-kah) LD (isotretinoin) capsules IMPORTANT: ABSORICA LD is not the same as ABSORICA or other isotretinoin generic products. Do not change between ABSORICA LD and ABSORICA or other isotretinoin generic products. Read the Medication Guide that comes with ABSORICA or ABSORICA LD before you start taking it and each time you get a prescription. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. What is the most important information I should know about ABSORICA and ABSORICA LD? • ABSORICA and ABSORICA LD can harm your unborn baby, including birth defects (deformed babies), loss of a baby before birth (miscarriage), death of the baby, and early (premature) births. Patients who are pregnant or who plan to become pregnant must not take ABSORICA or ABSORICA LD. Patients must not get pregnant: •for 1 month before starting ABSORICA or ABSORICA LD •during treatment with ABSORICA or ABSORICA LD •for 1 month after stopping ABSORICA or ABSORICA LD If you get pregnant during treatment with ABSORICA orABSORICALD, stop taking it right away and call your healthcare provider. Healthcare providers and patients should report all cases of pregnancy during treatment or 1 month after stopping treatment to: •FDA MedWatch at 1-800-FDA-1088, and •the iPLEDGE Pregnancy Registry at 1-866-495-0654 or www.ipledgeprogram.com Because ABSORICA and ABSORICA LD can cause birth defects, ABSORICA and ABSORICA LD are only for patients who can understand and agree to carry out all of the instructions in the iPLEDGE Program. • Serious mental health problems , including: • depression • psychosis (seeing or hearing things that are not real) • suicide. Some patients taking ABSORICA or ABSORICA LD have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. Some people have ended their own lives. Stop taking ABSORICA or ABSORICALD and call your healthcare provider right away if you or a family member notices that you have any of the following signs and symptoms of depression or psychosis: Your healthcare provider may tell you to see a mental healthcare professional if you had any of these symptoms. What are ABSORICA and ABSORICALD? ABSORICA and ABSORICA LD are prescription medicines used in patients 12 years of age and older, who are not pregnant, for the treatment of severe acne (nodular acne) that cannot be cleared up by any other acne treatments, including antibiotics. ABSORICA and ABSORICA LD can cause serious side effects (see “What is the most important information I should know about ABSORICA and ABSORICALD?” ). ABSORICA and ABSORICA LD can only be: •prescribed by healthcare providers that are registered in the iPLEDGE Program •dispensed by a pharmacy that is registered with the iPLEDGE Program •given to patients who are registered in the iPLEDGE Program and agree to do everything required in the program. It is not known if ABSORICA and ABSORICA LD are safe and effective in children less than 12 years of age. Do not take ABSORICA or ABSORICALD if you: 1. are pregnant, plan to become pregnant, or become pregnant during ABSORICA and ABSORICALD treatment. ABSORICA and ABSORICA LD cause severe birth defects. See “What is the most important information I should know about ABSORICA and ABSORICALD?” 2. are allergic to isotretinoin, vitamin A, or any of the ingredients in ABSORICA and ABSORICA LD. See the end of this Medication Guide for a complete list of ingredients in ABSORICA and ABSORICA LD. Before taking ABSORICA or ABSORICALD, tell your healthcare provider if you or a family member has any of the following health conditions: 1.mental health problems 2.asthma 3.liver problems 4.diabetes 5.heart disease 6.increase blood fat levels (cholesterol and triglycerides) 7.bone loss (osteoporosis), weak bones or any other bone problems 8.an eating problem called anorexia nervosa (where people eat too little) 9.food or medicine allergies, including aspirin or tartrazine Tell your healthcare provider if you are pregnant or breastfeeding. Do not breastfeed during treatment or for at least 8 days after the last dose of ABSORICA or ABSORICA LD. Tell your healthcare provider about all of the medicines you take including prescription and over-the-counter medicines, vitamins and herbal supplements, including St. John’s wort. ABSORICA and ABSORICA LD and certain other medicines can affect each other, sometimes causing serious side effects. Do not take the following medicines during treatment with ABSORICA or ABSORICA LD: •vitamin A supplements •tetracycline antibiotics Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist. Do not take any new medicine without talking with your healthcare provider. How should I take ABSORICA and ABSORICALD? You must take ABSORICA and ABSORICA LD exactly as prescribed. You must also follow all the instructions of the iPLEDGE Program. Before prescribing ABSORICA or ABSORICA LD, your healthcare provider will: 1.explain the iPLEDGE Program to you 2.have you sign the Patient Information/Informed Consent form (for all patients). Patients who can get pregnant must also sign another consent form. 3.give you a pregnancy test to make sure you are not pregnant before you start ABSORICA or ABSORICA LD. You will receive 2 pregnancy tests at least 19 days apart. You will not be prescribed ABSORICA or ABSORICALD if you cannot agree to or follow all the instructions of the iPLEDGE Program. •You will get no more than a 30-day supply of ABSORICA or ABSORICA LD at a time. This is to make sure you are following the ABSORICA and ABSORICA LD iPLEDGE Program. •The amount of ABSORICA or ABSORICA LD you take has been specially chosen for you. It is based on your body weight and may change during treatment. •Take ABSORICA or ABSORICA LD 2 times a day with or without meals, unless your healthcare provider tells you otherwise. Swallow your ABSORICA or ABSORICA LD capsules whole with a full glass of liquid. Do not chew or suck on the capsule. ABSORICA and ABSORICA LD can hurt the tube that connects your mouth to your stomach (esophagus) if not swallowed whole. •Your healthcare provider will tell you how long you will receive treatment with ABSORICA or ABSORICA LD. Your acne may continue to improve after treatment. •If you miss a dose, just skip that dose. Do not take two doses at the same time. •If you take too much ABSORICA or ABSORICA LD, call your healthcare provider or poison control center right away. •Your acne may get worse when you first start taking ABSORICA or ABSORICA LD. This should last only a short while. Talk with your healthcare provider if this is a concern for you. •You must return to your healthcare provider as directed to make sure you don’t have signs of serious side effects. Your healthcare provider may do blood tests to check for serious side effects from ABSORICA or ABSORICA LD and may stop treatment if you get certain side effects. •Patients who can get pregnant will get a pregnancy test each month, after you finish your course of treatment, and 1 month after you stop treatment with ABSORICA or ABSORICA LD. •Patients who can get pregnant must use two separate forms of birth control at the same time for at least 1 month before, during treatment, and for 1 month after treatment with ABSORICA or ABSORICA LD. You must access the iPLEDGE Program system to answer questions about the program requirements and to enter your two chosen forms of birth control. To access the iPLEDGE Program system, go to www.ipledgeprogram.com or call 1-866-495-0654. Talk about birth control options with your healthcare provider or go for a free visit to talk about birth control with another healthcare provider or family planning expert. Your healthcare provider can arrange this free visit, which will be paid for by the company that makes ABSORICA and ABSORICA LD. If you have sex at any time without using two forms of birth control 1 month before, during, or 1 month after treatment, get pregnant, or miss your expected period, stop taking ABSORICA orABSORICALD and call your healthcare provider right away. What should I avoid while taking ABSORICA orABSORICALD? 1. Do not give blood during treatment with ABSORICA or ABSORICA LD and for one month after stopping ABSORICA or ABSORICA LD. If someone who is pregnant gets your donated blood, their baby may be exposed to isotretinoin and may be born with birth defects. 2. Do not take other medicines or herbal products with ABSORICA or ABSORICA LD unless you talk to your healthcare provider. See “Before taking ABSORICA or ABSORICALD” 3. Do not drive at night until you know if ABSORICA or ABSORICALD has affected your vision. ABSORICA and ABSORICA LD may decrease your ability to see in the dark. 4. Do not have cosmetic procedures to smooth your skin, including waxing, dermabrasion, or laser procedures, during treatment withABSORICA or ABSORICALD and for at least 6 months after you stop. ABSORICA and ABSORICA LD can increase your chance of scarring from these procedures. Check with your healthcare provider for advice about when you can have cosmetic procedures. 5. Avoid sunlight and ultraviolet lights as much as possible. Tanning machines use ultraviolet lights. ABSORICA and ABSORICA LD may make your skin more sensitive to light. 6. Do not share ABSORICA or ABSORICALD with other people .ABSORICA and ABSORICA LD can cause birth defects and other serious health problems. What are the possible side effects of ABSORICA and ABSORICALD? ABSORICA and ABSORICA LD can cause serious side effects, including: 1.See “ What is the most important information I should know about ABSORICA and ABSORICA LD ”? 2. increased pressure in the brain (intracranial hypertension). ABSORICA and ABSORICA LD can increase the pressure in your brain. This can lead to permanent loss of eyesight, and in rare cases, death. Stop taking ABSORICA or ABSORICA LD and call your healthcare provider right away if you get any of these signs of increased brain pressure: 3. serious skin problems. Skin rash can occur in patients taking ABSORICA or ABSORICA LD. Sometimes rash can be serious and may lead to death. Stop using ABSORICA or ABSORICA LD and call your healthcare provider right away if you get: 4. inflammation of your pancreas (pancreatitis) can happen in patients who take ABSORICA or ABSORICA LD and can lead to death. Call your healthcare provider right away if you have any of the following symptoms of pancreatitis: 5. increased blood fat (lipid) levels. ABSORICA and ABSORICA LD can raise blood fat levels (cholesterol and triglycerides). Your healthcare provider will do blood tests to check your lipids before and during treatment. These problems usually go away when ABSORICA or ABSORICA LD treatment is finished. 6. hearing problems. Stop using ABSORICA or ABSORICA LD and call your healthcare provider if your hearing gets worse or if you have ringing in your ears. Your hearing loss may be permanent. 7. liver problems, including hepatitis. Your healthcare provider will do tests to check your liver before and during treatment with ABSORICA or ABSORICA LD. Call your healthcare provider if you get: 8. inflammation of your digestive tract (inflammatory bowel disease). Stop taking ABSORICA or ABSORICA LD and call your healthcare provider if you get: 9. bone and muscle problems. Bone problems include bone pain, softening or thinning (which may lead to fractures). Tell your healthcare provider if you plan hard physical activity during treatment with ABSORICA or ABSORICA LD. Tell your healthcare provider if you get: 10.back pain 11.joint pain or muscle pain 12.broken bone. Tell all healthcare providers that you take ABSORICA or ABSORICA LD if you break a bone. Stop ABSORICA orABSORICALD and call your healthcare provider right away if you have muscle weakness. Muscle weakness with or without pain can be a sign of serious muscle damage. ABSORICA and ABSORICA LD may stop long bone growth in teenagers who are still growing. 13. vision problems. Stop taking ABSORICA or ABSORICA LD and call your healthcare provider right away if you have any vision changes. ABSORICA and ABSORICA LD may affect your ability to see in the dark. This usually goes away after you stop taking ABSORICA or ABSORICA LD, but it may be permanent. Some patients get dry eyes during treatment. If you wear contact lenses, you may have trouble wearing them during and after you stop treatment with ABSORICA or ABSORICA LD. 14. serious allergic reactions. Stop taking ABSORICA or ABSORICA LD and get emergency medical help right away if you get hives, a swollen face or mouth, or have trouble breathing. Stop taking ABSORICA or ABSORICA LD and call your healthcare provider if you get a fever, rash, or red patches or bruises on your legs. 15. blood sugar problems, including diabetes . Tell your healthcare provider if you are very thirsty or urinate more than usual. The most common side effects of ABSORICA and ABSORICALD include: These are not all of the possible side effects of ABSORICA and ABSORICA LD. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Sun Pharmaceutical Industries, Inc. at 1-800-818-4555. How should I store ABSORICA and ABSORICALD? 1.Store ABSORICA and ABSORICA LD at room temperature, 68°F to 77°F (20°C to 25°C). Protect from light. Keep ABSORICA and ABSORICALD and all medicines out of the reach of children. General Information about the safe and effective use of ABSORICA and ABSORICALD Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ABSORICA or ABSORICA LD for a condition for which it was not prescribed. Do not give ABSORICA or ABSORICA LD to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about ABSORICA and ABSORICA LD that is written for health professionals. You can also call iPLEDGE Program at 1-866-495-0654 or visit www.ipledgeprogram.com . What are the ingredients in ABSORICA and ABSORICALD? Active ingredient: isotretinoin Inactive ingredients in ABSORICA: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems: •10 mg – iron oxide (yellow) and titanium dioxide •20 mg – iron oxide (red), and titanium dioxide •25 mg – FD&C Blue #1, FD&C Yellow #5 , FD&C Yellow #6 and titanium dioxide •30 mg – iron oxide (black, red and yellow) and titanium dioxide •35 mg – FD&C Blue #2, iron oxide (black, red and yellow) and titanium dioxide •40 mg – iron oxide (black, red and yellow) and titanium dioxide Inactive ingredients in ABSORICA LD: butylated hydroxy anisole, gelatin, hard gelatin capsule shell, polysorbate 80, and soybean oil. The gelatin capsules contain the following dye systems: •8 mg – D&C Yellow #10, FD&C Blue #1, FD&C Red #40 and titanium dioxide •16 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •20 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •24 mg – D&C Yellow #10, FD&C Yellow #6 and titanium dioxide •28 mg – FD&C Blue #1, FD&C Red #40, and titanium dioxide •32 mg – ferrosoferric oxide, ferric oxide (red and yellow) and titanium dioxide The imprinting ink of 8 mg, 16 mg, 24 mg and 32 mg capsules contain the following ingredients: potassium hydroxide, propylene glycol, shellac and titanium dioxide. The imprinting ink of 20 mg and 28 mg capsules contain the following ingredients: ferrosoferric oxide, propylene glycol and shellac glaze. ABSORICA LD 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg is protected by US Patent No. US 9,700,535 and US 9,750,711. All trademarks are property of their respective owners. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512

14 CLINICAL STUDIES The effectiveness of ABSORICA/ABSORICA LD for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older has been established and is based on a double-blind, randomized, parallel group trial (Study 1) in subjects with severe recalcitrant nodular acne who received ABSORICA or another isotretinoin capsule product under fed conditions. A total of 925 subjects were randomized 1:1 to receive ABSORICA or another isotretinoin capsule product. Study subjects ranged from 12 to 54 years of age (including 397 pediatric subjects 12 to 17 years old); 60% were male, 40% were female; and the racial groups included 87% White, 4% Black, 6% Asian, and 3% Other. Enrolled subjects had a weight of 40 to 110 kg and had at least 10 nodular lesions on the face and/or trunk. Subjects were treated with an initial dose of 0.5 mg/kg/day in two divided doses for the first 4 weeks, followed by 1 mg/kg/day in two divided doses for the following 16 weeks. Change from baseline to Week 20 in total nodular lesion count and proportion of subjects with at least a 90% reduction in total nodular lesion count from baseline to Week 20 are presented in Table 3. Total nodular lesion counts by visit are presented in Figure 1. A single course of ABSORICA and another isotretinoin capsule product therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of acne in many patients. Table 3: Efficacy Results in Subjects with Severe Recalcitrant Nodular Acne at Week 20 (Study 1) ABSORICA N=464 Another Isotretinoin Capsule Product* N=461 Nodular Lesions Mean Baseline Count Mean Reduction 18.4 -15.68 17.7 -15.62 Subjects Achieving 90% Reduction, n (%) 324 (70%) 344 (75%) Figure 1: Total Nodular (Facial and Truncal) Lesion Count in Subjects with Severe Recalcitrant Nodular Acne by Visit in Study 1 * Another isotretinoin capsule product. spl-absorica-figure-1

15 REFERENCES 1.Cinar SL, Kartal D, Aksoy H, et al. Long-term effect of systemic isotretinoin on female fertility. Cutan Ocul Toxicol. 2017;36(2):132-134.

8.5 Geriatric Use Clinical studies of ABSORICA/ABSORICA LD did not include sufficient numbers of geriatric subjects (subjects aged 65 years of age and older) to determine whether they respond differently from younger adults. Although reported clinical experience has not identified differences in responses between geriatric and younger adults, effects of aging may increase some risks associated with ABSORICA/ABSORICA LD therapy.

8.3 Females and Males of Reproductive Potential All patients who can become pregnant must comply with the iPLEDGE program requirements [see Warnings and Precautions (5.2) ]. Pregnancy Testing ABSORICA/ABSORICA LD must only be prescribed to patients who are known not to be pregnant as confirmed by a negative CLIA-certified laboratory conducted pregnancy test. Patients who can become pregnant must have had two negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial ABSORICA/ABSORICA LD prescription (the interval between the two tests must be at least 19 days). • The first test (a screening test) is obtained by the prescriber when the decision is made to prescribe ABSORICA/ABSORICA LD therapy. • The second pregnancy test (a confirmation test) is performed after the patient has used 2 forms of contraception for 1 month and during the first 5 days of the menstrual period immediately preceding the beginning of ABSORICA/ABSORICA LD therapy (for patients with regular menstrual cycles) or immediately preceding the beginning of ABSORICA/ABSORICA LD therapy (for patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding). A pregnancy test must be repeated each month, in a CLIA-certified laboratory prior to the patient receiving each prescription. A pregnancy test must also be completed at the end of the entire course of ABSORICA/ABSORICA LD therapy and 1 month after the discontinuation of ABSORICA/ABSORICA LD. Contraception Patients who can become pregnant must use 2 forms of contraception simultaneously, at least 1 of which must be a primary form, for at least 1 month prior to initiation of ABSORICA/ABSORICA LD therapy, during ABSORICA/ABSORICA LD therapy, and for 1 month after discontinuing ABSORICA/ABSORICA LD therapy. However, 2 forms of contraception is not required if the patient commits to continuous abstinence from not having any sexual contact with a partner which may result in pregnancy, has undergone a hysterectomy or bilateral oophorectomy, or has been medically confirmed to be post-menopausal. Micro-dosed progesterone preparations (“minipills” that do not contain an estrogen) are an inadequate method of contraception during ABSORICA/ABSORICA LD therapy. Primary forms Secondary forms •Tubal sterilization Barrier: •Male vasectomy •male latex condom with or without spermicide •Intrauterine device •diaphragm with spermicide •Hormonal (combination oral contraceptives, vaginal systems, vaginal inserts, transdermal systems, injections, or implants) •cervical cap with spermicide Other: •Vaginal sponge (contains spermicide) Any birth control method can fail. There have been reports of pregnancy from patients who have used combination oral contraceptives, as well as contraceptive vaginal systems, vaginal inserts, transdermal systems, and injections; these pregnancies occurred while taking isotretinoin. These reports are more frequent for patients who use only a single method of contraception. Therefore, it is critically important that patients who can become pregnant use 2 methods of contraception simultaneously. A clinical drug interaction study did not show any clinically significant interaction between isotretinoin and norethindrone and ethinyl estradiol; however, it is not known if there is an interaction between isotretinoin with other progestins [see Drug Interactions (7.5) ]. Prescribers are advised to consult the prescribing information of any medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products. Patients who can become pregnant should be prospectively cautioned not to self-medicate with the herbal supplement St. John’s Wort because of a possible interaction with hormonal contraceptives based on reports of breakthrough bleeding on oral contraceptives shortly after starting St. John’s Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John’s Wort. If the patient has unprotected sexual contact with a partner that could result in pregnancy at any time 1 month before, during, or 1 month after therapy, the patient must: 1. Stop taking ABSORICA/ABSORICA LD immediately, if on therapy 2. Have a pregnancy test at least 19 days after the last act of unprotected sexual contact with a partner that could result in pregnancy 3. Start using 2 forms of contraception simultaneously again for 1 month before resuming ABSORICA/ABSORICA LD therapy 4. Have a second pregnancy test after using 2 forms of contraception for 1 month. Infertility In a trial of female acne patients (n = 79) receiving another isotretinoin capsule product, the mean total ovarian volume, the total antral follicle count and mean anti-Mullerian hormone decreased at the end of the treatment (sixth month). However, the values returned to normal at the 18 th month (12 months after the end of treatment). There were no statistically significant changes in terms of follicle-stimulating hormone and luteinizing hormone, both at the end of the treatment and 12 months after the end of treatment. Although the results suggest that possible deteriorative effects of isotretinoin on ovarian reserve may be reversible, the study has important methodological limitations, including a small sample size, lack of a control group, and lack of generalizability. Sperm Study In trials of 66 men, 30 of whom were patients with nodular acne under treatment with oral isotretinoin, no significant changes were noted in the count or motility of spermatozoa in the ejaculate. In a study of 50 men (ages 17 to 32 years) receiving isotretinoin therapy for nodular acne, no significant effects were seen on ejaculate volume, sperm count, total sperm motility, morphology or seminal plasma fructose.

8.4 Pediatric Use The safety and effectiveness of ABSORICA/ABSORICA LD for the treatment of severe recalcitrant nodular acne have been established in pediatric subjects ages 12 to 17 years. Use of ABSORICA/ABSORICA LD in this age group for this indication is supported by evidence from a clinical trial (Study 1) that compared the use ABSORICA to another isotretinoin capsule product in 397 pediatric subjects (12 to 17 years) [see Clinical Studies (14) ] and pharmacokinetic data in pediatric subjects [see Clinical Pharmacology (12.3) ] . The safety and effectiveness of ABSORICA/ABSORICA LD in pediatric patients less than 12 years of age have not been established. Adverse Reactions in Pediatric Subjects In trials with isotretinoin capsules, adverse reactions reported in pediatric subjects aged 12 to 17 years old were similar to those described in adults except for the increased incidence of back pain and arthralgia (both of which were sometimes severe) and myalgia in pediatric subjects. In a trial of pediatric subjects aged 12 to 17 years old treated with isotretinoin capsules, approximately 29% (104/358) developed back pain. Back pain was severe in 14% (14/104) of the cases and occurred at a higher frequency in female subjects than male subjects. Arthralgias were experienced in 22% (79/358) of pediatric subjects including severe arthralgias in 8% (6/79) of subjects. Appropriate evaluation of the musculoskeletal system should be done in adolescents who present with these symptoms during or after a course of ABSORICA/ABSORICA LD. Consider discontinuing ABSORICA/ABSORICA LD if any significant abnormality is found. Effects on Bone Mineral Density in Pediatric Subjects The effect on bone mineral density (BMD) of a 20-week course of therapy with ABSORICA or another isotretinoin capsule product was evaluated in a double-blind, randomized clinical trial involving 396 adolescents with severe recalcitrant nodular acne (mean age 15.4 years old, range 12 to 17 years old, 80% males). Given that there were no statistically significant differences between the two isotretinoin capsule groups following 20 weeks of treatment, the results are presented for the pooled treatment groups. The mean changes in BMD from baseline for the overall trial population were 1.8% for lumbar spine, -0.1% for total hip and -0.3% for femoral neck. Mean BMD Z-scores declined from baseline at each of these sites (-0.053, -0.109 and -0.104 respectively). Out of 306 adolescents, 27 (9%) had clinically significant BMD declines defined as ≥4% lumbar spine or total hip, or ≥5% femoral neck, including 2 subjects for lumbar spine, 17 for total hip and 20 for femoral neck. Repeat DXA scans within 2 to 3 months after the post treatment scan showed no recovery of BMD. Long-term follow-up at 4 to 11 months showed that 3 out of 7 subjects had total hip and femoral neck BMD below pre-treatment baseline, and 2 others did not show the increase in BMD above baseline expected in this adolescent population. The significance of these changes in regard to long-term bone health and future fracture risk is unknown [see Warnings and Precautions (5.12) ] . In an open-label clinical trial (N=217) of a single course of therapy with isotretinoin capsules for adolescents with severe recalcitrant nodular acne, BMD at several skeletal sites were not significantly decreased (lumbar spine change >-4% and total hip change >-5%) or were increased in the majority of subjects. One patient had a decrease in lumbar spine BMD >4% based on unadjusted data. Sixteen (8%) subjects had decreases in lumbar spine BMD >4%, and all the other subjects (92%) did not have significant decreases or had increases (adjusted for body mass index). Nine subjects (5%) had a decrease in total hip BMD >5% based on unadjusted data. Twenty-one (11%) subjects had decreases in total hip BMD >5%, and all the other subjects (89%) did not have significant decreases or had increases (adjusted for body mass index). Follow-up trials performed in 8 of the subjects with decreased BMD for up to 11 months thereafter demonstrated increasing BMD in 5 subjects at the lumbar spine, while the other 3 subjects had lumbar spine BMD measurements below baseline values. Total hip BMD remained below baseline (range −1.6% to −7.6%) in 5 of 8 subjects (63%). In a separate open-label extension trial of 10 subjects including those ages 13 to 17 years, who started a second course of isotretinoin capsules 4 months after the first course, two subjects showed a decrease in mean lumbar spine BMD up to 3.3%. Epiphyseal Closure There are reports of premature epiphyseal closure in acne patients who used isotretinoin at recommended doses. The effect of multiple courses of isotretinoin on epiphyseal closure is unknown. In a 20-week clinical trial that included 289 adolescents who had hand radiographs taken to assess bone age, a total of 9 subjects had bone age changes that were clinically significant and for which an isotretinoin-related effect cannot be excluded [see Warnings and Precautions (5.12) ] .

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to isotretinoin during pregnancy. Report any suspected fetal exposure during or 1 month after ABSORICA/ABSORICA LD therapy immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet ( www.ipledgeprogram.com ). Risk Summary ABSORICA/ABSORICA LD are contraindicated during pregnancy because isotretinoin can cause fetal harm when administered to a pregnant patient. There is an increased risk of major congenital malformations, spontaneous abortions, and premature births following isotretinoin exposure during pregnancy in humans. If ABSORICA/ABSORICA LD is used during pregnancy, or if the patient becomes pregnant while taking ABSORICA/ABSORICA LD, the patient should be apprised of the potential hazard to a fetus. If pregnancy occurs during treatment of a patient who is taking ABSORICA/ABSORICA LD, ABSORICA/ABSORICA LD must be discontinued immediately and the patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Data Human Data Major congenital malformations that have been documented following isotretinoin exposure include malformations of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. External malformations include: skull; ear (including anotia, micropinna, small or absent external auditory canals); eye (including microphthalmia); facial dysmorphia and cleft palate. Internal abnormalities include: CNS (including cerebral and cerebellar malformations, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular; thymus gland; parathyroid hormone deficiency. In some cases, death has occurred as a result of the malformations. Cases of IQ scores less than 85 with or without other abnormalities have been reported in children exposed in utero to isotretinoin. An increased risk of spontaneous abortion and premature births have been reported with isotretinoin exposure during pregnancy.

8 USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding not recommended (8.2) . 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to isotretinoin during pregnancy. Report any suspected fetal exposure during or 1 month after ABSORICA/ABSORICA LD therapy immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet ( www.ipledgeprogram.com ). Risk Summary ABSORICA/ABSORICA LD are contraindicated during pregnancy because isotretinoin can cause fetal harm when administered to a pregnant patient. There is an increased risk of major congenital malformations, spontaneous abortions, and premature births following isotretinoin exposure during pregnancy in humans. If ABSORICA/ABSORICA LD is used during pregnancy, or if the patient becomes pregnant while taking ABSORICA/ABSORICA LD, the patient should be apprised of the potential hazard to a fetus. If pregnancy occurs during treatment of a patient who is taking ABSORICA/ABSORICA LD, ABSORICA/ABSORICA LD must be discontinued immediately and the patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Data Human Data Major congenital malformations that have been documented following isotretinoin exposure include malformations of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. External malformations include: skull; ear (including anotia, micropinna, small or absent external auditory canals); eye (including microphthalmia); facial dysmorphia and cleft palate. Internal abnormalities include: CNS (including cerebral and cerebellar malformations, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular; thymus gland; parathyroid hormone deficiency. In some cases, death has occurred as a result of the malformations. Cases of IQ scores less than 85 with or without other abnormalities have been reported in children exposed in utero to isotretinoin. An increased risk of spontaneous abortion and premature births have been reported with isotretinoin exposure during pregnancy. 8.2 Lactation Risk Summary There are no data on the presence of isotretinoin in either animal or human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in nursing infants from isotretinoin, advise patients that breastfeeding is not recommended during treatment with ABSORICA/ABSORICA LD, and for at least 8 days after the last dose of ABSORICA/ABSORICA LD. 8.3 Females and Males of Reproductive Potential All patients who can become pregnant must comply with the iPLEDGE program requirements [see Warnings and Precautions (5.2) ]. Pregnancy Testing ABSORICA/ABSORICA LD must only be prescribed to patients who are known not to be pregnant as confirmed by a negative CLIA-certified laboratory conducted pregnancy test. Patients who can become pregnant must have had two negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial ABSORICA/ABSORICA LD prescription (the interval between the two tests must be at least 19 days). • The first test (a screening test) is obtained by the prescriber when the decision is made to prescribe ABSORICA/ABSORICA LD therapy. • The second pregnancy test (a confirmation test) is performed after the patient has used 2 forms of contraception for 1 month and during the first 5 days of the menstrual period immediately preceding the beginning of ABSORICA/ABSORICA LD therapy (for patients with regular menstrual cycles) or immediately preceding the beginning of ABSORICA/ABSORICA LD therapy (for patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding). A pregnancy test must be repeated each month, in a CLIA-certified laboratory prior to the patient receiving each prescription. A pregnancy test must also be completed at the end of the entire course of ABSORICA/ABSORICA LD therapy and 1 month after the discontinuation of ABSORICA/ABSORICA LD. Contraception Patients who can become pregnant must use 2 forms of contraception simultaneously, at least 1 of which must be a primary form, for at least 1 month prior to initiation of ABSORICA/ABSORICA LD therapy, during ABSORICA/ABSORICA LD therapy, and for 1 month after discontinuing ABSORICA/ABSORICA LD therapy. However, 2 forms of contraception is not required if the patient commits to continuous abstinence from not having any sexual contact with a partner which may result in pregnancy, has undergone a hysterectomy or bilateral oophorectomy, or has been medically confirmed to be post-menopausal. Micro-dosed progesterone preparations (“minipills” that do not contain an estrogen) are an inadequate method of contraception during ABSORICA/ABSORICA LD therapy. Primary forms Secondary forms •Tubal sterilization Barrier: •Male vasectomy •male latex condom with or without spermicide •Intrauterine device •diaphragm with spermicide •Hormonal (combination oral contraceptives, vaginal systems, vaginal inserts, transdermal systems, injections, or implants) •cervical cap with spermicide Other: •Vaginal sponge (contains spermicide) Any birth control method can fail. There have been reports of pregnancy from patients who have used combination oral contraceptives, as well as contraceptive vaginal systems, vaginal inserts, transdermal systems, and injections; these pregnancies occurred while taking isotretinoin. These reports are more frequent for patients who use only a single method of contraception. Therefore, it is critically important that patients who can become pregnant use 2 methods of contraception simultaneously. A clinical drug interaction study did not show any clinically significant interaction between isotretinoin and norethindrone and ethinyl estradiol; however, it is not known if there is an interaction between isotretinoin with other progestins [see Drug Interactions (7.5) ]. Prescribers are advised to consult the prescribing information of any medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products. Patients who can become pregnant should be prospectively cautioned not to self-medicate with the herbal supplement St. John’s Wort because of a possible interaction with hormonal contraceptives based on reports of breakthrough bleeding on oral contraceptives shortly after starting St. John’s Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John’s Wort. If the patient has unprotected sexual contact with a partner that could result in pregnancy at any time 1 month before, during, or 1 month after therapy, the patient must: 1. Stop taking ABSORICA/ABSORICA LD immediately, if on therapy 2. Have a pregnancy test at least 19 days after the last act of unprotected sexual contact with a partner that could result in pregnancy 3. Start using 2 forms of contraception simultaneously again for 1 month before resuming ABSORICA/ABSORICA LD therapy 4. Have a second pregnancy test after using 2 forms of contraception for 1 month. Infertility In a trial of female acne patients (n = 79) receiving another isotretinoin capsule product, the mean total ovarian volume, the total antral follicle count and mean anti-Mullerian hormone decreased at the end of the treatment (sixth month). However, the values returned to normal at the 18 th month (12 months after the end of treatment). There were no statistically significant changes in terms of follicle-stimulating hormone and luteinizing hormone, both at the end of the treatment and 12 months after the end of treatment. Although the results suggest that possible deteriorative effects of isotretinoin on ovarian reserve may be reversible, the study has important methodological limitations, including a small sample size, lack of a control group, and lack of generalizability. Sperm Study In trials of 66 men, 30 of whom were patients with nodular acne under treatment with oral isotretinoin, no significant changes were noted in the count or motility of spermatozoa in the ejaculate. In a study of 50 men (ages 17 to 32 years) receiving isotretinoin therapy for nodular acne, no significant effects were seen on ejaculate volume, sperm count, total sperm motility, morphology or seminal plasma fructose. 8.4 Pediatric Use The safety and effectiveness of ABSORICA/ABSORICA LD for the treatment of severe recalcitrant nodular acne have been established in pediatric subjects ages 12 to 17 years. Use of ABSORICA/ABSORICA LD in this age group for this indication is supported by evidence from a clinical trial (Study 1) that compared the use ABSORICA to another isotretinoin capsule product in 397 pediatric subjects (12 to 17 years) [see Clinical Studies (14) ] and pharmacokinetic data in pediatric subjects [see Clinical Pharmacology (12.3) ] . The safety and effectiveness of ABSORICA/ABSORICA LD in pediatric patients less than 12 years of age have not been established. Adverse Reactions in Pediatric Subjects In trials with isotretinoin capsules, adverse reactions reported in pediatric subjects aged 12 to 17 years old were similar to those described in adults except for the increased incidence of back pain and arthralgia (both of which were sometimes severe) and myalgia in pediatric subjects. In a trial of pediatric subjects aged 12 to 17 years old treated with isotretinoin capsules, approximately 29% (104/358) developed back pain. Back pain was severe in 14% (14/104) of the cases and occurred at a higher frequency in female subjects than male subjects. Arthralgias were experienced in 22% (79/358) of pediatric subjects including severe arthralgias in 8% (6/79) of subjects. Appropriate evaluation of the musculoskeletal system should be done in adolescents who present with these symptoms during or after a course of ABSORICA/ABSORICA LD. Consider discontinuing ABSORICA/ABSORICA LD if any significant abnormality is found. Effects on Bone Mineral Density in Pediatric Subjects The effect on bone mineral density (BMD) of a 20-week course of therapy with ABSORICA or another isotretinoin capsule product was evaluated in a double-blind, randomized clinical trial involving 396 adolescents with severe recalcitrant nodular acne (mean age 15.4 years old, range 12 to 17 years old, 80% males). Given that there were no statistically significant differences between the two isotretinoin capsule groups following 20 weeks of treatment, the results are presented for the pooled treatment groups. The mean changes in BMD from baseline for the overall trial population were 1.8% for lumbar spine, -0.1% for total hip and -0.3% for femoral neck. Mean BMD Z-scores declined from baseline at each of these sites (-0.053, -0.109 and -0.104 respectively). Out of 306 adolescents, 27 (9%) had clinically significant BMD declines defined as ≥4% lumbar spine or total hip, or ≥5% femoral neck, including 2 subjects for lumbar spine, 17 for total hip and 20 for femoral neck. Repeat DXA scans within 2 to 3 months after the post treatment scan showed no recovery of BMD. Long-term follow-up at 4 to 11 months showed that 3 out of 7 subjects had total hip and femoral neck BMD below pre-treatment baseline, and 2 others did not show the increase in BMD above baseline expected in this adolescent population. The significance of these changes in regard to long-term bone health and future fracture risk is unknown [see Warnings and Precautions (5.12) ] . In an open-label clinical trial (N=217) of a single course of therapy with isotretinoin capsules for adolescents with severe recalcitrant nodular acne, BMD at several skeletal sites were not significantly decreased (lumbar spine change >-4% and total hip change >-5%) or were increased in the majority of subjects. One patient had a decrease in lumbar spine BMD >4% based on unadjusted data. Sixteen (8%) subjects had decreases in lumbar spine BMD >4%, and all the other subjects (92%) did not have significant decreases or had increases (adjusted for body mass index). Nine subjects (5%) had a decrease in total hip BMD >5% based on unadjusted data. Twenty-one (11%) subjects had decreases in total hip BMD >5%, and all the other subjects (89%) did not have significant decreases or had increases (adjusted for body mass index). Follow-up trials performed in 8 of the subjects with decreased BMD for up to 11 months thereafter demonstrated increasing BMD in 5 subjects at the lumbar spine, while the other 3 subjects had lumbar spine BMD measurements below baseline values. Total hip BMD remained below baseline (range −1.6% to −7.6%) in 5 of 8 subjects (63%). In a separate open-label extension trial of 10 subjects including those ages 13 to 17 years, who started a second course of isotretinoin capsules 4 months after the first course, two subjects showed a decrease in mean lumbar spine BMD up to 3.3%. Epiphyseal Closure There are reports of premature epiphyseal closure in acne patients who used isotretinoin at recommended doses. The effect of multiple courses of isotretinoin on epiphyseal closure is unknown. In a 20-week clinical trial that included 289 adolescents who had hand radiographs taken to assess bone age, a total of 9 subjects had bone age changes that were clinically significant and for which an isotretinoin-related effect cannot be excluded [see Warnings and Precautions (5.12) ] . 8.5 Geriatric Use Clinical studies of ABSORICA/ABSORICA LD did not include sufficient numbers of geriatric subjects (subjects aged 65 years of age and older) to determine whether they respond differently from younger adults. Although reported clinical experience has not identified differences in responses between geriatric and younger adults, effects of aging may increase some risks associated with ABSORICA/ABSORICA LD therapy.

16 HOW SUPPLIED/STORAGE AND HANDLING ABSORICA and ABSORICA LD have different dosage regimens. Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable [see Dosage and Administration (2.1) ] . ABSORICA ABSORICA (isotretinoin) Capsules (opaque) are supplied as follows: • 10 mg : Dark yellow, capsule imprinted with black ink “G 240” on cap and “10” on the body • Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-115-31 • 20 mg : Red, capsule imprinted with black ink “G 241” on cap and “20” on the body • Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-116-31 • 25 mg : Green, capsule imprinted with white ink “G 342” on cap and “25” on the bodyBox of 30 capsules (3 x 10 Prescription Packs): NDC 10631-133-31 • 30 mg : Brown, capsule imprinted with white ink “G 242” on cap and “30” on the bodyBox of 30 capsules (3 x 10 Prescription Packs): NDC 10631-117-31 • 35 mg : Dark blue, capsule imprinted with white ink “G 343” on cap and “35” on the bodyBox of 30 capsules (3 x 10 Prescription Packs): NDC 10631-134-31 • 40 mg : Brown and red, capsule imprinted with white ink “G 325” on cap and “40” on the bodyBox of 30 capsules (3 x 10 Prescription Packs): NDC 10631-118-31 ABSORICA LD ABSORICA LD (isotretinoin) Capsules (opaque-printed, hard-gelatin) are supplied as follows: • 8 mg: A size 3, light green, capsules banded with a colorless band. The cap is printed in white with “RL29” and the body is printed in white with “RL29”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-002-31 • 16 mg: A size 2, dark blue, capsules banded with a colorless band. The cap is printed in white with “RL30” and the body is printed in white with “RL30”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-003-31 • 20 mg: A size 1, dark pink, capsules banded with a colorless band. The cap is printed in black with “RL33”and the body is printed in black with “RL33”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-004-31 • 24 mg: A size 1, yellow, capsules banded with a colorless band. The cap is printed in white with “RL31” and the body is printed in white with “RL31”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-005-31 • 28 mg: A size 0, light blue, capsules banded with a colorless band. The cap is printed in black with “RL34” and the body is printed in black with “RL34”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-006-31 • 32 mg: A size 0, caramel, capsules banded with a colorless band. The cap is printed in white with “RL32” and the body is printed in white with “RL32”. Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-007-31 Storage and Handling of ABSORICA and ABSORICA LD Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Protect from light.

WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY ABSORICA/ABSORICA LD can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of ABSORICA/ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue ABSORICA/ABSORICA LD immediately and refer the patient to an Obstetrician- Gynecologist experienced in reproductive toxicity for further evaluation and counseling [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Because of the risk of embryo-fetal toxicity, ABSORICA and ABSORICA LD are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE REMS [see Warnings and Precautions (5.2) ] . WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY See full prescribing information for complete boxed warning. • ABSORICA/ABSORICA LD can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking ABSORICA/ABSORICA LD in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. ( 4 , 5.1 , 8.1 ) • ABSORICA/ABSORICA LD are available only through a restricted program called the iPLEDGE ® REMS. ( 5.2 )